Adrenomedullin 2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases

作者：Zhang, Song-Yang; Xu, Ming-Jiang^*; Wang, Xian

来源：British Journal of Pharmacology, 2018, 175(8): 1230-1240.

DOI：10.1111/bph.13814

• CENTRAL-NERVOUS-SYSTEM
• ENDOPLASMIC-RETICULUM STRESS
• COUNTER-REGULATORY PEPTIDE
• NITRIC-OXIDE
• BLOOD-PRESSURE
• CONCISE GUIDE
• INTERMEDIN ADRENOMEDULLIN-2
• INSULIN-RESISTANCE
• FAMILY PEPTIDE
• INTERMEDIN/ADRENOMEDULLIN 2

Adrenomedullin (ADM) 2/intermedin (IMD) is a short peptide that belongs to the CGRP superfamily. Although it shares receptors with CGRP, ADM and amylin, ADM2 has significant and unique functions in the cardiovascular system. In the past decade, the cardiovascular effect of ADM2 has been carefully analysed. In this review, progress in understanding the effects of ADM2 on the cardiovascular system and its protective role in cardiometabolic diseases are summarized. @@@ Linked ArticlesThis article is part of a themed section on Spotlight on Small Molecules in Cardiovascular Diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.8/issuetoc

• 出版日期2018-4
• 单位北京大学